Agios to Present New Clinical Data from its IDH Programs at ASCO
– Updated Data From Ivosidenib Phase 1 Expansion in IDH1m R/R AML and the
– New Data From Fully Enrolled Ivosidenib Arm of the Phase 1/2 Combination Trial of Enasidenib or Ivosidenib with VIDAZA® in Newly Diagnosed AML to be Featured in Poster Presentation –
In total, five abstracts led by Agios describing new data from the company's IDH programs have been accepted for presentation at
The accepted abstracts are listed below and are available online on the
Oral presentations by Agios:
Title: Phase 1 Study of AG-881, an Inhibitor of Mutant IDH1/IDH2, in Patients with Advanced IDH-mutant Solid Tumors, Including Glioma
Date & Time:
Oral Abstract Session: Central Nervous System Tumors
Abstract: 2002
Location: S102
Presenter: Ingo K. Mellinghoff, M.D.,
Title: Ivosidenib (IVO; AG-120) in Mutant IDH1 Relapsed/Refractory AML: Results of a Phase 1 Study
Date & Time:
Oral Abstract Session: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant
Abstract: 7000
Location: E450
Presenter:
This abstract has been selected as part of the “Best of ASCO” program to be presented in cities across the country. “Best of ASCO” features the top abstracts, highlighting the most cutting-edge science and education from the annual meeting.
Poster presentations by Agios and/or
Title: Mutant IDH (mIDH) Inhibitors, Ivosidenib or Enasidenib, with Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML)
Poster Session Date & Time:
Poster Session: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant
Abstract: 7042
Poster Board: 102
Poster Location: Hall A
Author:
Title: AGILE: A Phase 3, Multicenter, Randomized, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adult Patients with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation
Poster Session Date & Time:
Poster Session: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant
Abstract: TPS7074
Poster Board: 133b
Poster Location: Hall A
Author:
Title: Pharmacokinetics/pharmacodynamics (PK/PD) of Ivosidenib in Patients with IDH1-mutant Advanced Solid Tumors from a Phase 1 Study
Poster Session Date & Time:
Poster Session: Developmental Therapeutics – Clinical Pharmacology and Experimental Therapeutics
Abstract: 2577
Poster Board: 403
Poster Location: Hall A
Author: Bin Fan, Ph.D.,
Title: Clinical pharmacokinetics/pharmacodynamics (PK/PD) of Ivosidenib in Patients with IDH1-mutant Advanced Hematologic Malignancies from a Phase 1 Study
Poster Session Date & Time:
Poster Session: Developmental Therapeutics – Clinical Pharmacology and Experimental Therapeutics
Abstract: 2581
Poster Board: 407
Poster Location: Hall A
Author:
About Agios
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has an approved oncology precision medicine and multiple first-in-class investigational therapies in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.
About Agios/Celgene Collaboration
IDHIFA® (enasidenib) and AG-881 are part of Agios' global strategic collaboration with Celgene Corporation focused on cancer metabolism. Under the terms of the 2010 collaboration agreement, Celgene has worldwide development and commercialization rights for IDHIFA® (enasidenib). Agios continues to conduct certain clinical development activities within the IDHIFA® (enasidenib) development program and is eligible to receive reimbursement for those development activities and up to $95 million in remaining payments assuming achievement of certain milestones, and royalties on any net sales. Celgene and Agios are currently co-commercializing IDHIFA® (enasidenib) in the U.S. Celgene will reimburse Agios for costs incurred for its co-commercialization efforts. For AG-881, the companies have a joint worldwide development and 50/50 profit share collaboration, and Agios is eligible to receive regulatory milestone payments of up to $70 million.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the potential benefits of Agios' product candidates, including IDHIFA®, ivosidenib, and AG-881; its plans regarding future data presentations; and the potential benefit of its strategic plans and focus. The words “anticipate,” “expect,” “intend,” “potential,” “milestone,” “goal,” “will,” “on track,” “upcoming,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios' current expectations and beliefs. For example, there can be no guarantee that any product candidate Agios or its collaborator,
Contacts
Investors:
Senior Manager, Investor Relations
Renee.Leck@agios.com
Media:
Associate Director, Corporate Communications
Holly.Manning@agios.com
Source: Agios Pharmaceuticals, Inc.